NCT03907423

Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin

Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Rehab Werida · Academic / Other
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients treated with glimepiride/metformin without coronary artery disease. This effect will be investigated especially on sortilin ,fetuin-A

Detailed description

A randomized controlled trial on 70 patients with DM type 2 will be recruited from Damanhour national medical institute. * Subjects will be divided into two group (one arm is DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients) and another arm is DM-type 2 patient who will receive glimepiride-metformin combination (30 patients). * Determination of serum levels of fetuin A and Sortilin * Blood samples will be collected after 3-month after active treatment. * Outcomes measurement : Sortilin ,fetuinA, Atherogenic index (AI) and coronary risk index (CRI) . Methodology * Sortilin, fetuinA will be determined by ELISA. * Lipid profile. * FBG and Hb A1C will be measured. * Atherogenic index (AI = LDL-C/HDL-C) and CRI (CRI = TC/HDL-C) will be calculated for all subjects.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Rosuvastatin10 mg tablet	Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
DRUG	Placebo Oral Tablet	Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral

Timeline

• Start date: 2019-04-01
• Primary completion: 2021-01-19
• Completion: 2021-01-31
• First posted: 2019-04-09
• Last updated: 2023-04-14

Locations

1 site across 1 country: Egypt